MCL1 and diffuse large B-cell lymphoma: Although we determined that the combination of venetoclax and an MCL1 inhibitor was synergistic and overcame venetoclax resistance in DLBCL, the clinical development of MCL1 inhibitors is impeded by cardiac toxicity, likely through an apoptosis-independent mechanism in cardiomyocytes [10,68].